Loading...

Joinn Laboratories(China)Co.,Ltd.

6127.HK•HKSE
Healthcare
Medical - Diagnostics & Research
HK$16.68
HK$0.54(3.35%)

Joinn Laboratories(China)Co.,Ltd. (6127.HK) Stock Overview

Explore Joinn Laboratories(China)Co.,Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-15.07%
↓ 15.07%
Profit Growth
HK$0.47
↓ 81.34%
EPS Growth
HK$0.47
↓ 81.13%
Operating Margin
22.55%
↓ 79.42%
ROE
4.83%
↓ 81.34%
Dividend Yield
0.00%
↓ 43.54%
Analyst Recommendations data is not available for 6127.HKAnalyst Recommendations details for 6127.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics studies, and pharmacology and efficacy studies. The Clinical Trial and Related Services segment provides clinical CRO services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment designs, produces, breeds, and sells research models, non-human primates, and rodents. The company also offers investment management and cell-based assay (CBA) services. Joinn Laboratories(China)Co.,Ltd. was founded in 1995 and is headquartered in Beijing, China.

CEO

Dr. Yuxia Feng M.D.

Employees

2,510

Headquarters

A5 Rongjing East Street, Beijing

Founded

2021

Frequently Asked Questions